Millions of Americans are not taking their GLP-1 drugs as prescribed
First reported Fri, 13 Nov 2026 21:59:01 GMT · Last updated

GLP-1 medications are everywhere these days. The peptide-based drugs are both highly effective and wildly popular for diabetes, weight loss and a growing range of connected chronic health conditions, including cardiovascular disease and obstructive sleep apnea. But, amid the boom, the latest data suggests millions of Americans have turned to unapproved versions and are using the potent drugs in ways doctors never intended, raising questions about what that real-world use means for safety and efficacy. In a study published this week , researchers at the Centers for Disease Control and Prevention broke down survey data of GLP-1 use collected between July and August of 2025. Based on responses from over 8,000 US adults, the researchers estimate that about one in 10 US adults (9.8 percent) used a glucagon-like peptide-1 receptor agonist, aka GLP-1 medication, in 2025. That's around 27 million adults. The study was published in the CDC's Morbidity and Mortality Weekly Report. Among GLP-1 users, nearly half (44 percent) reported using their GLP-1 in a way that was different from how it was prescribed. Users skipped doses, delayed getting refills, and used smaller doses than prescribed, a
1 source in this cluster
- Ars TechnicaMillions of Americans are not taking their GLP-1 drugs as prescribed
GLP-1 medications are everywhere these days. The peptide-based drugs are both highly effective and wildly popular for diabetes, weight loss and a growing range of connected chronic health conditions, including cardiovascular disease and obstructive sleep apnea. But, amid the boom, the latest data suggests millions of Americans have turned to unapproved versions and are using the potent drugs in ways doctors never intended, raising questions about what that real-world use means for safety and efficacy. In a study published this week , researchers at the Centers for Disease Control and Prevention broke down survey data of GLP-1 use collected between July and August of 2025. Based on responses from over 8,000 US adults, the researchers estimate that about one in 10 US adults (9.8 percent) used a glucagon-like peptide-1 receptor agonist, aka GLP-1 medication, in 2025. That's around 27 million adults. The study was published in the CDC's Morbidity and Mortality Weekly Report. Among GLP-1 users, nearly half (44 percent) reported using their GLP-1 in a way that was different from how it was prescribed. Users skipped doses, delayed getting refills, and used smaller doses than prescribed, a
Fri, 13 Nov 2026 21:59:01 GMT
Timeline
- 2026-11-13 21:59Ars Technica — Millions of Americans are not taking their GLP-1 drugs as prescribed
How to read this page
- Headlines, quotes and facts come from the linked original articles (reporting).
- "Newsei analysis" and "Why it matters" are AI-assisted synthesis (inference).
- "Confirmed" means two or more independent outlets reported the same claim.
Methodology · Source profiles & bias labels · Corrections policy · Report an error: info@newsei.com
Share this timeline
Embed shows this story's live timeline on your own site and links back here.